drugset
drugset / Trial / NCT05045482

Hepatic Impairment With Cirrhosis Due to Cholestatic Liver Disease

NCT05045482 ↗

Phase 1 Recruiting 30 enrolled Zydus Therapeutics Inc.
Non-randomizedParallel-groupOpen-labelTreatment

Summary

A Phase 1, Open-label Extension Groups Study in Subjects having Hepatic Impairment with Cirrhosis due to Cholestatic Liver Disease

Timeline

Start
2021-10-21
Primary completion
2026-03-31
Completion
2026-03-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Saroglitazar Small molecule 1 mg —
Subject Saroglitazar Small molecule 2 mg —

Indications

cholestasis cirrhosis of liver